BBOT Stock Forecast & Price Target

BridgeBio Oncology is attractive fundamentally because its pipeline is concentrated on RAS-driven cancers, where the addressable opportunity is large and the company’s internally linked programs create rational combination upside across CRC and PDAC. BBO-8520 has shown a differentiated clinical profile in 2L+ NSCLC, with a 63% ORR, 100% DCR, 75% of evaluable patients still on treatment beyond six months, and no grade 3 liver enzyme elevations, supporting both efficacy and safer checkpoint-inhibitor pairing potential. The strategic focus on BBO-11818 and BBO-10203, plus preclinical evidence of deeper tumor regressions and an estimated about $7.5bn in total worldwide peak sales across modeled indications, suggests meaningful long-term value despite near-term pipeline pruning.

BridgeBio Oncology is weakened by an early-stage pipeline concentrated in three Phase 1 assets, where BBO-8520, BBO-10203, and BBO-11818 still lack proof of durable efficacy, a sufficient therapeutic window, or a clear registrational path. The decision to streamline the pipeline and deprioritize breast cancer, while sensible competitively, removes potential upside and highlights how crowded the KRAS and broader RAS landscape has become, with multiple rival programs already in late-stage development or producing stronger early data. With no debt but likely future equity needs for large randomized Phase 3 trials, the company faces meaningful dilution risk, while regulatory, safety, and commercialization uncertainty leave its valuation highly exposed to disappointing clinical readouts.